Host: The Japanese Society of Toxicology
Name : The 47th Annual Meeting of the Japanese Society of Toxicology
Date : 2020 -
Liquid biopsy (LB) such as circulating tumor cells, circulating tumor DNA, and exosomes places great expectations on clinical application for solid cancer patietns.
Plasma EGFR mutation test was approved as companion diagnostics for 3rd generation of EGFR-tyrosine kinase inhibitors (TKIs). Technological innovation using digital PCR and ultra-sensitive next-generation sequencers drives the clinical application of liquid biopsy.
Copy number gain and methylation of circulating tumor DNA as well as gene mutation could be analyzed using LB. The purposes of LB are prediction of the effects of molecular targeted drugs and immune checkpoint inhibitors, early detection of cancer, and proof of concept of the drugs. LB-based minimal residual disease (MDR) monitoring is gathering worldwide attention as a field of clinical implementation. In this presentation, we report on clinical applications of LB for precision oncology, including our own studies.
